echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Active Ingredient News > Immunology News > Ann Rheum Dis: Nidanib's safety and tolerance for systemic sclerosis-related interstitiotic pulmonary disease.

    Ann Rheum Dis: Nidanib's safety and tolerance for systemic sclerosis-related interstitiotic pulmonary disease.

    • Last Update: 2020-09-24
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com
    Nidanib is a drug used to treat idiotic pulmonary fibrosis.
    study describes the safety and tolerance of Nidanib in systemic sclerosis-associated interstitiotic pulmonary disease (SSc-ILD), as well as dose adjustment for adverse events.
    in the SENSCIS trial, SSc-ILD patients were randomly divided into two groups and treated with 150 mg nidanib (twice a day) or a placebo.
    to control adverse events, the treatment can be stopped or the dose reduced to 100 mg (twice daily).
    assessed adverse events and dose adjustments over a 52-week period.
    results were as follows: a total of 576 patients were treated with nidanib (n=288) or placebo (n=288).
    most common adverse events were diarrhea, which occurred in 75.7 per cent of patients in the Nidanib group and 31.6 per cent in the placebo group, respectively.
    6.9 percent of patients in the Nidanib group and 0.3 percent in the placebo group had permanent suspension due to diarrhea, respectively.
    48.3% and 12.2% of patients in the nidanib group and 12.2% of patients in the nidanib group had had a reduction and/or suspension of the drug, respectively, and 16.0% and 8.7% of the patients had been permanently suspended due to adverse events.
    were similar to Nidanib-related adverse events in different age, gender, race, and weight subgroups.
    the dose was adjusted anyway, the rate of decrease in forced lung capacity was similar in patients in the Nidanib group.
    result, nidanib's adverse event characteristics in SSc-ILD patients are consistent with safety and tolerance in idynapathic pulmonary fibrosis.
    dose adjustment is important to minimize the effects of adverse events and to help patients continue treatment.
    .
    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.